Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Haloperidol

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Haloperidol Testmiljö

Haloperidol

Klass : C

Visa all info

Skriv ut

Kontakta oss

  1. de Leon J, Diaz FJ, Wedlund P, Josiassen RC, Cooper TB, Simpson GM. Haloperidol half-life after chronic dosing. J Clin Psychopharmacol. 2004;24(6):656-60.

  2. Desai M, Tanus-Santos JE, Li L, Gorski JC, Arefayene M, Liu Y et al. Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6. Pharmacogenomics J. 2003;3(2):105-13.

  3. McEvoy JP, Johnson J, Perkins D, Lieberman JA, Hamer RM, Keefe RS et al. Insight in first-episode psychosis. Psychol Med. 2006;36(10):1385-93.

  4. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154:457-65.

  5. Ascher-Svanum H, Stensland M, Zhao Z, Kinon BJ. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry. 2005;5:3.

  6. Goldstein JM, Cohen LS, Horton NJ, Lee H, Andersen S, Tohen M et al. Sex differences in clinical response to olanzapine compared with haloperidol. Psychiatry Res. 2002;110:27-37.

  7. Brettner F, Janitza S, Prüll K, Weninger E, Mansmann U, Küchenhoff H et al. Gender-Specific Differences in Low-Dose Haloperidol Response for Prevention of Postoperative Nausea and Vomiting: A Register-Based Cohort Study. PLoS One. 2016;11(1):e0146746.

  8. Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev. 2002;1(2):CD002852.

  9. Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int. 2011;108:687-93.

  10. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-22.

  11. Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Hum Psychopharmacol. 2008;23(3):201-9.

  12. Bobes J, Garc A-Portilla MP, Rejas J, Hern Ndez G, Garcia-Garcia M, Rico-Villademoros F et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther. 2003;29(2):125-47.

  13. Dossenbach M, Dyachkova Y, Pirildar S, Anders M, Khalil A, Araszkiewicz A et al. Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Psychiatry. 2006;21(4):251-8.

  14. David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther. 2000;22(9):1085-96.

  15. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology. 2003;28 Suppl 2(1):69-82.

  16. Wudarsky M, Nicolson R, Hamburger SD, Spechler L, Gochman P, Bedwell J et al. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol. 1999;9(4):239-45.

  17. Knol W, van Marum RJ, Jansen PA, Strengman E, Al Hadithy AF, Wilffert B et al. Genetic variation and the risk of haloperidol-related parkinsonism in elderly patients: a candidate gene approach. J Clin Psychopharmacol. 2013;33(3):405-10.

  18. Jung DU, Conley RR, Kelly DL, Kim DW, Yoon SH, Jang JH et al. Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study. J Clin Psychiatry. 2006;67(9):1391-6.

  19. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-08-19.]

  1. de Leon J, Diaz FJ, Wedlund P, Josiassen RC, Cooper TB, Simpson GM. Haloperidol half-life after chronic dosing. J Clin Psychopharmacol. 2004;24(6):656-60.
  2. Desai M, Tanus-Santos JE, Li L, Gorski JC, Arefayene M, Liu Y et al. Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6. Pharmacogenomics J. 2003;3(2):105-13.
  3. McEvoy JP, Johnson J, Perkins D, Lieberman JA, Hamer RM, Keefe RS et al. Insight in first-episode psychosis. Psychol Med. 2006;36(10):1385-93.
  4. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154:457-65.
  5. Ascher-Svanum H, Stensland M, Zhao Z, Kinon BJ. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry. 2005;5:3.
  6. Goldstein JM, Cohen LS, Horton NJ, Lee H, Andersen S, Tohen M et al. Sex differences in clinical response to olanzapine compared with haloperidol. Psychiatry Res. 2002;110:27-37.
  7. Brettner F, Janitza S, Prüll K, Weninger E, Mansmann U, Küchenhoff H et al. Gender-Specific Differences in Low-Dose Haloperidol Response for Prevention of Postoperative Nausea and Vomiting: A Register-Based Cohort Study. PLoS One. 2016;11(1):e0146746.
  8. Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev. 2002;1(2):CD002852.
  9. Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int. 2011;108:687-93.
  10. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-22.
  11. Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Hum Psychopharmacol. 2008;23(3):201-9.
  12. Bobes J, Garc A-Portilla MP, Rejas J, Hern Ndez G, Garcia-Garcia M, Rico-Villademoros F et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther. 2003;29(2):125-47.
  13. Dossenbach M, Dyachkova Y, Pirildar S, Anders M, Khalil A, Araszkiewicz A et al. Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Psychiatry. 2006;21(4):251-8.
  14. David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther. 2000;22(9):1085-96.
  15. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology. 2003;28 Suppl 2(1):69-82.
  16. Wudarsky M, Nicolson R, Hamburger SD, Spechler L, Gochman P, Bedwell J et al. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol. 1999;9(4):239-45.
  17. Knol W, van Marum RJ, Jansen PA, Strengman E, Al Hadithy AF, Wilffert B et al. Genetic variation and the risk of haloperidol-related parkinsonism in elderly patients: a candidate gene approach. J Clin Psychopharmacol. 2013;33(3):405-10.
  18. Jung DU, Conley RR, Kelly DL, Kim DW, Yoon SH, Jang JH et al. Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study. J Clin Psychiatry. 2006;67(9):1391-6.
  19. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-08-19.]